Research programme: anti-R24 monoclonal antibodies - Viragen

Drug Profile

Research programme: anti-R24 monoclonal antibodies - Viragen

Alternative Names: Anti-GD3 monoclonal antibody - Viragen; Anti-R24 monoclonal antibody - Viragen; VG 101

Latest Information Update: 08 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Viragen
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 08 May 2007 Discontinued - Preclinical for Malignant melanoma in USA (IV-infusion)
  • 10 Nov 2004 Preclinical trials in Malignant melanoma in USA (IV-infusion)
  • 27 Jul 2004 The anti-R24 monoclonal antibody is available for licensing (http://www.viragen.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top